

Vigmed granted additional patent in the US.

The US Patent and Trademark office has announced to Vigmed that it intends to grant the Company an additional patent for their needle protecting solution found in the product lines CLiP® and SWiTCH®.

Vigmed has earlier been granted patents for the needle protecting solution CLiP®, and systems comprising CLiP®. This patent will broaden Vigmed's scope of protection, and additionally give the Company protection for another feature of CLiP® and SWiTCH®.

Vigmed has filed, nationally and internationally, more than 80 patents and patent applications based on more than three innovation platforms. The company owns all its patents and patent applications without any restrictions. The basic patents all have a maximum validity period.

Vigmed's strategy is to protect the Company's technology and products in all geographical areas deemed to be of importance. Vigmed intends to expand its patent portfolio continuously on both the offensive and defensive patent and utility model rights based on a number of new innovation platforms.

For further
information contact:

CEO
Henrik Olsen
+46 42 600 5320 or

R&D Director
Fredrik Thörne,
+46 42 600 5312

Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed's share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company's Certified Advisor. Additional information about the company can be found on Vigmed's website: www.vigmed.com/investor